Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling.

Hai T. Tran,Vincent K. Lam,Yasir Elamin,Lingzhi Hong,Rivka R. Colen,Nabil Elshafeey,Islam Hassan,Mehmet Altan,George R. Blumenschein,Waree Rinsurongkawong,Melvin J Rivera,Mayra E. Vasquez,Brett W. Carter,Lauren E Byers,Anne S. Tsao,Don L. Gibbons,Frank V. Fossella,Bonnie S. Glisson,Jianjun Zhang,John V. Heymach

Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling.

2021

PURPOSETo compare clinical outcomes in a cohort of patients with advanced non–small-cell lung cancer (NSCLC) with targetable genomic alterations detected using plasma-based circulating tumor DNA (c...

Keywords:

genomic profiling
Cancer research
non small cell
EGFR Tyrosine Kinase Inhibitors
Lung cancer
Medicine
Circulating tumor DNA
Cohort

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations